These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5016100)

  • 21. [Sociological aspects of ambulatory neuroleptic therapy in Italy].
    Rossi R; Seminara B; Arcioli I; Gabriello F; Giuffra F
    Hyg Ment; 1969; 58(2):33-60. PubMed ID: 5379090
    [No Abstract]   [Full Text] [Related]  

  • 22. [Studies on a long-acting neuroleptic of the butyrophenone group with special reference to the neuroleptic threshold].
    Haase HJ; Koester H; Wahl G
    Med Welt; 1967 Nov; 44():2652-8. PubMed ID: 6076058
    [No Abstract]   [Full Text] [Related]  

  • 23. [Psycho-pharmacological study of a 5th butyrophenone: "methylperidide", a neuroleptic pyrrolidinamide and methyl derivative of haloperidol].
    DIVRY P; BOBON J; COLLARD J; DEMARET A
    Acta Neurol Psychiatr Belg; 1960 Dec; 60():1073-86. PubMed ID: 13723131
    [No Abstract]   [Full Text] [Related]  

  • 24. [The neuroleptic effects of the piperazine derivative of butyrophenone (MD-2028)].
    CHAUCHARD P; MAZOUE H
    C R Seances Soc Biol Fil; 1961; 155():29-31. PubMed ID: 24545495
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical trial of a new psychopharmacological agent: piperonyl].
    Gazzaniga GC; Terzi GF
    Riv Sper Freniatr Med Leg Alien Ment; 1971 Aug; 95(4):799-807. PubMed ID: 5114798
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacodynamic activation of the electroencephalogram: place of fluanisone].
    Labat J; Fournier A; Gardey P; Guelain J
    Rev Corps Sante Armees Terre Mer Air; 1969 Aug; 10(4):429-43. PubMed ID: 4245981
    [No Abstract]   [Full Text] [Related]  

  • 27. [A new neuroleptic with delayed hypnogenic effect: dipiperon (R3345), butyrophenone carbamide].
    BOBON J; COLLARD J; DEMARET A
    Acta Neurol Psychiatr Belg; 1961 Jul; 61():611-30. PubMed ID: 13870300
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diagnostic utilization in clinical EEG of a neuroleptic butyrophenone: MD-2028].
    MORIN G; BOUCHACOURT A; VIGNOT P; COULONJOU R
    Presse Med (1893); 1961 Apr; 69():915-6. PubMed ID: 13772666
    [No Abstract]   [Full Text] [Related]  

  • 29. [Character disorders and their treatment by pipamperone].
    Fouks ; Périvier ; Houssalt ; Gilbert ; Ferragu
    Ann Med Psychol (Paris); 1968 Feb; 1(2):255-8. PubMed ID: 5651948
    [No Abstract]   [Full Text] [Related]  

  • 30. [Present possibilities and prospects in the treatment of Huntington's chorea].
    Petit H
    Therapeutique; 1972 Nov; 48(9):605-8. PubMed ID: 4265448
    [No Abstract]   [Full Text] [Related]  

  • 31. [Psychodynamic and sociodynamic changes produced by methylperidol].
    Leal R
    Actas Luso Esp Neurol Psiquiatr; 1969 Oct; 28(4):299-305. PubMed ID: 5394271
    [No Abstract]   [Full Text] [Related]  

  • 32. [Psychopharmacology of a third neuroleptic from the butyrophenone series: R 2498 or triperidol].
    DIVRY P; BOBON J; COLLARD J; DEMARET A
    Acta Neurol Psychiatr Belg; 1960 May; 60():465-80. PubMed ID: 13816974
    [No Abstract]   [Full Text] [Related]  

  • 33. [Use of a neuroleptic agent of the butyrophenone series (2028 MD) in clinical E.E.G].
    MORIN G; VIGNOT P; BOUCHACOURT A
    Rev Neurol (Paris); 1960 Sep; 103():272-5. PubMed ID: 13772670
    [No Abstract]   [Full Text] [Related]  

  • 34. [A NEW MAJOR NEUROLEPTIC AGENT: TRIPERIDOL. 1ST CLINICAL RESULTS OBTAINED WITH A NEW BUTYROPHENONE DERIVATIVE].
    DUBOIS C; DICK P; REY-BELLET J
    Schweiz Med Wochenschr; 1963 Nov; 93():1600-4. PubMed ID: 14153115
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical use of butyrophenones].
    Gerle B
    Nord Psykiatr Tidsskr; 1968; 22(2):100-6. PubMed ID: 5704624
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined treatment with ECT and antipsychotic drugs in schizophrenia.
    Weinstein MR; Fischer A
    Dis Nerv Syst; 1971 Dec; 32(12):801-8. PubMed ID: 5139202
    [No Abstract]   [Full Text] [Related]  

  • 37. [Loss of visual acuity after treatment with pipamperone].
    Loos D; Kook P; Huber J; Zorn C; Lohmann CP; Zapp D; Maier M
    Ophthalmologe; 2011 Aug; 108(8):763-5. PubMed ID: 21717227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haldol in the treatment of children with tics and stutterers--and an incidental finding.
    Tapia F
    Psychiatr Q; 1969; 43(4):647-9. PubMed ID: 5366363
    [No Abstract]   [Full Text] [Related]  

  • 39. factors influencing response to major tranquilizer medications.
    Kimbell I; Overall JE; Faibish GM; Pokorny AD
    Dis Nerv Syst; 1972 Apr; 33(4):223-30. PubMed ID: 5029910
    [No Abstract]   [Full Text] [Related]  

  • 40. Withdrawal of antiparkinson drugs.
    Orlov P; Kasparian G; DiMascio A; Cole JO
    Arch Gen Psychiatry; 1971 Nov; 25(5):410-2. PubMed ID: 5133814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.